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ABSTRACT: Control of elemental impurities in pharmaceutical materials is currently undergoing a transition from control based on
concentrations in components of drug products to control based on permitted daily exposures in drug products. Within the pharmaceutical
community, there is uncertainty regarding the impact of these changes on manufactures of drug products. This uncertainty is fueled
in part by a lack of publically available information on elemental impurity levels in common pharmaceutical excipients. This paper
summarizes a recent survey of elemental impurity levels in common pharmaceutical excipients as well as some drug substances. A
widely applicable analytical procedure was developed and was shown to be suitable for analysis of elements that are subject to United
States Pharmacopoeia Chapter <232> and International Conference on Harmonization’s Q3D Guideline on Elemental Impurities. The
procedure utilizes microwave-assisted digestion of pharmaceutical materials and inductively coupled plasma mass spectrometry for
quantitative analysis of these elements. The procedure was applied to 190 samples from 31 different excipients and 15 samples from eight
drug substances provided through the International Pharmaceutical Excipient Council of the Americas. The results of the survey indicate
that, for the materials included in the study, relatively low levels of elemental impurities are present. C© 2015 The Authors. Journal of
Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:4197–4206,
2015
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Mass Spectrometry; Regulatory Science
INTRODUCTION
Procedures for controlling elemental impurities in pharmaceu-
tical products are undergoing significant revision. Elemental
impurity levels in pharmaceutical materials are currently con-
trolled through concentration specifications for metal catalysts
and reagents in drug substances and/or concentration-based
compendial acceptance criteria for select elements or classes
of elements in drug substances and excipients. For some ma-
terials, pharmaceutical manufacturers currently demonstrate
that they meet the compendial limits on drug substances and
excipients by applying pharmacopeial heavy metals tests based
on sulfide precipitation such as the procedure described in the
United States Pharmacopeia (USP) General Chapter <231>
Heavy Metals.1 These acceptance criteria are being replaced
by element specific permitted daily exposures (PDEs) from fin-
ished drug products that are based on current toxicological as-
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sessments of the elements. The PDE concept was firmly estab-
lished in the International Conference on Harmonization (ICH)
Q3C guideline on residual solvents. These major changes in the
control of elemental impurities in pharmaceutical products are
the culmination of many years of discussion and planning.
In 1995, the USP published a stimuli article in Pharma-
copeial Forum describing several problems with the sulfide pre-
cipitation method including poor, variable recoveries, lack of
selectivity, loss of volatile elements, and questionable validity.2
The article recommended the use of spiked control samples dur-
ing validation and substitution of atomic absorption and other
instrumental methods for USP <231>. In 1998, the European
Medicines Agency (EMA) began to develop a guideline on resid-
ual catalysts in pharmaceuticals with the goal of establishing
limits based on toxicological safety assessments of common cat-
alytic elements.3 In 2008, the EMA Guideline on Specification
Limits for Residues of Metal Catalysts or Metal Reagents was
officially implemented for new drug products. The EMA guide-
line introduced mass-based PDEs to establish permissible ex-
posures in drug products rather than concentration limits in
drug substances. The PDEs in the EMA guideline were based
on assessments of toxicological data on individual metals.
Between 2000 and 2008, the USP initiated a series of work-
shops and stakeholder forums for the purpose of revising
General Chapter <231> Heavy Metals. During this time, sev-
eral papers evaluated the suitability of modern instrumental
methods of analysis for elemental impurities in pharmaceuti-
cal articles and products.4–6 In 2008, the USP commissioned the
United States Institute of Medicine to organize a workshop to
evaluate current elemental toxicology and capabilities of mod-
ern methods of elemental analysis. Later in 2008, the USP
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proposed to replace <231> with two chapters: <232>, which
would establish safety based limits on elemental impurities in
pharmaceutical products, and <233> which would establish
appropriate criteria for methods for elemental analysis.7 Af-
ter several years of revision with input from a broad group of
stakeholders, these chapters were finalized, and became official
in February of 2013.
In 2009, the ICH initiated the Q3D expert working group
on elemental impurities in pharmaceutical products with the
intention of harmonizing technical requirements for elemen-
tal impurities in pharmaceutical products across three regions:
Europe, Japan, and the US.8 As with the EMA guideline and
the USP chapters, the Q3D expert working group endeavored
to set maximum PDEs for elemental impurities in pharmaceu-
tical products based on an assessment of existing toxicological
data for the oral, parenteral and inhalation routes of adminis-
tration. Q3D reached Step 2 of the ICH process in June, 2013
and the guideline was published for public review and com-
ment. Q3D reached step 4 in November of 2014, and the USP
Expert Panel on Elemental Impurities aligned General Chap-
ters <232> and <233> with Q3D to the extent possible.
A PDE is the total daily mass of an impurity which is con-
sidered safe on the basis of direct toxicity. This is now a well-
established approach which limits the amount of an impurity
that is ingested by the patient rather than setting concentration
limits on pharmaceutical materials. However, when applied to
elemental impurities in drug products, the PDE approach poses
some challenges for users and suppliers of drug substances
and excipients because measurable acceptance criteria are no
longer imposed on individual components of the drug product.
Rather, the drug product manufacturer must determine what
concentrations of elemental impurities are permissible for a
drug product on the basis of the mass of a maximum daily dose
of the drug product and the element-specific PDEs. Elemental
impurity levels in drug products may also be controlled by set-
ting appropriate concentration limits on all components of a
drug product, based on the mass of each component of the drug
product.
Manufacturers and suppliers of drug substances and excipi-
ents are understandably concerned about the impact of the new
standards and guidelines on the requirements for elemental im-
purities in their products. At present, when applicable, ingre-
dient manufacturers demonstrate that their products comply
with compendial concentration limits for elemental impurities.
There is concern that pharmaceutical manufacturers may now
request extensive quantitative assessment of all elemental im-
purities in the components of drug products to demonstrate
that the drug products comply with the new standards and
meet the recommendations of new guidances. Currently there
is a dearth of publically available data on elemental impurity
levels in most pharmaceutical ingredients, which imposes ad-
ditional uncertainty on the impact of these new standards and
guidances.
The purpose of this paper is to present a survey of elemental
impurity concentrations in a variety of excipients commonly
used in pharmaceutical products as well as some drug sub-
stances. The samples for this survey were provided by the
members of International Pharmaceutical Excipient Council-
Americas (IPEC-Americas), and were analyzed at the United
States Food and Drug Administration (US FDA) Division of
Pharmaceutical Analysis. The analysis of these materials uti-
lized a robustmethod of closed vessel digestionwhich is suitable
for a wide variety of excipients and drug substances with appro-
priate modification, and the digested samples were analyzed
by inductively coupled plasma mass spectrometry (ICP-MS).
The experimental section of this paper describes the details
of the analytical procedure. This is followed by the analytical
results and a description of the capabilities of the procedures.
The paper concludes with a brief discussion of some analytical
challenges, and some potential solutions to those challenges.
EXPERIMENTAL
Reagents and Materials
Concentrated nitric acid (70%), concentrated hydrochloric acid
(37%), hydrogen peroxide (30%), and hydrofluoric acid (49%)
were purchased fromFisher Scientific (Fair Lawn, New Jersey).
All of these regents were trace metal grade. Diluted
nitric acid and hydrochloric acid were used for analytical so-
lutions and sample dilutions. 18 M-cm deionized water was
produced through a Milli-Q water purification system (Milli-
pore, Bedford, Massachusetts). Multi-element standards and
individual standards were purchased from High-Purity Stan-
dards (Charleston, South Carolina). Instrument tuning solu-
tion and pulse/analog (P/A) tuning solution were purchased
fromAgilent Technologies (Newport, Delaware). Metal-free pol-
propylene centrifuge tubes 15 mL and 50 mL were purchased
from VWR (Radnor, Pennsylvania).
One hundred and ninety pharmaceutical excipient samples
and 15 drug substance sampleswere supplied by excipientman-
ufacturers through IPEC-Americas. The samples included 31
different excipients that are commonly used in pharmaceutical
manufacturing and eight different drug substances, and many
were provided from multiple manufacturers and in several lots
from the samemanufacturer. The samples were coded by IPEC-
Americas’ counsel before being shipped to the US FDADivision
of Pharmaceutical Analysis such that the analysts were in-
formed of the name of each material, but were blind to their
precise lot number and origin, which were only known to coun-
sel. Different manufacturers were denoted with letters, and dif-
ferent lots were denoted with numbers to convey information
on material variability without disclosing the specific products
under test.
Instrumentation
All quantitative analyses were performed with an Agilent
7700x quadruple ICP-MS system and a model ASX-500 Au-
tosampler (Agilent Technologies). Standard, sample, and qual-
ity control solutions were delivered to the nebulizer via a peri-
staltic pump at 0.1 mL per minute, and the nebulizer converted
the sample solution to a spray mist using gas (Ar). For most
samples in this study, a glass nebulizer was used, but when
hydrogen fluoride was included in the digestion cocktail a per-
fluoroalkoxyalkane nebulizer was used. The peristaltic pump
also continuously delivered a multi-element solution contain-
ing lithium-6, scandium, yttrium, indium, terbium, holmium,
lutetium, and bismuth to the nebulizer. These elements, deliv-
ered at a fixed composition relative to the sample flow rate,
were used as internal standards to compensate for matrix ef-
fects and instrumental instabilities during analysis. Internal
standards were selected for each elemental analyte such that
their first ionization energies were similar and interferences
were minimized.
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Table 1. ICP–MS Instrumental Operational Conditions and Data
Acquisition Parameters
Standard Collision
Mode Gas Mode
RF power (W) 1550 1550
Plasma gas flow rate
(L min−1)
14.97 14.97
Dilution gas flow rate
(L min−1)
0.55 0.55
Nebulizer gas flow
rate (L min−1)
0.6 0.6
Collision gas flow
rate (mL min−1)
n.a. 4.5 (He) or 6.0 (High
He)
Nebulizer MicroMist
(Borosilicate glass,
id 0.5 mm)
MicroMist
(Borosilicate glass,
id 0.5 mm)
Spray chamber Quartz, Scott-type Quartz, Scott-type
Torch Quartz, id 2.5 mm Quartz, id 2.5 mm
Sampler and
skimmer cones
Nickel Nickel
Lens voltage (V) 7.6 7.6
Scan mode Peak hopping Peak hopping
Detector Electron multiplier
detector
Electron multiplier
detector
Dwell time (s) 0.1 0.1
Sweeps 100 100
Readings/replicates 3 3
The instrument is equipped with an octopole collision
cell utilizing 99.999% purity helium gas to deflect molecular
interferents from the ion path as discussed below. Instrumental
settings were optimized daily prior to analysis using a tuning
solution containing Li, Co, Ce, Tl, and Y to establish system
suitability. Automated adjustments to the torch alignment, de-
tector voltage, and ion lens voltages optimized resolution, sen-
sitivity, and stability across a broad range of masses. The dou-
bly charged ion ratio (Ce2+ to Ce+), and oxide ratio (CeO+ to
Ce+) were also monitored, and were maintained below 5% and
2%, respectively. Three collision gas conditions were used: no
gas, helium gas, and high helium gas, as described below. The
isotopic masses under investigation were scanned under one
or more collision gas conditions with an equilibration time of
30 s between conditions to pressurize or evacuate the collision
cell. Typical instrumental and operating conditions are given in
Table 1, and a typical, automated measurement of a single
sample for all elements under all conditions described above
required approximately 5 min.
Samples were prepared by closed vessel acid digestion using
a Milestone Ethos Series SK-10 microwave digestion system
with segmented rotor vessels (Milestone Inc., Shelton, Con-
necticut). The microwave digestion system is equipped with
temperature and pressure sensors. In some cases, the pressure
sensor was used for digestion method development, but the
method parameters are based on temperature control and so
pressure was not routinely controlled during sample digestion.
The Teflon vessels have a volume of 100 mL, a maximum pres-
sure of 100 bar and a maximum temperature of 300°C. This
system features a “vent-and-reseal” design that prevents over-
pressure without losing samples. A typical time-temperature
digestion cycle was to ramp to 190°C over 10 min, hold at 190°C
for 20 min, and cool to room temperature. With this system,
10 samples can be digested simultaneously.
Table 2. Concentration Range of ICP–MS Calibration and Limit of
Detection
Standard Limit of
Q3D Concentration Detection
Class Element Isotope Range (ng g−1) (LOD) (ng g−1)
1 Cd 111 0.5–50 0.038
Pb 208 0.5–50 0.058
As 75 0.5–50 0.050
Hg 202 0.01–1.0 0.040
2A Co* 59 0.5–50 0.042
V 51 0.5–50 0.194
Ni 60 0.5–50 0.074
2B Tl* 205 0.5–50 0.086
Au* 197 0.01–1.0 0.019
Pd 105 0.02–2.0 0.152
Ir 193 0.01–1.0 0.003
Os 189 0.01–1.0 0.134
Rh 103 0.01–1.0 0.002
Ru 101 0.01–1.0 0.002
Se* 78 0.5–50 0.652
Ag* 107 0.5–50 0.005
Pt 195 0.01–1.0 0.003
3 Li* 7 0.5–50 0.187
Sb* 121 0.5–50 0.099
Ba* 137 0.5–50 0.362
Mo 95 0.5–50 0.237
Cu 63 0.5–50 0.804
Sn* 118 0.5–50 0.162
Cr 52 0.5–50 0.051
Asterisks denote elements that are included in ICH Q3D, but not in
USP <232>.
Standard Preparation
Four standard concentrations plus a blank solution were used
to prepare calibration curves for each element. The calibration
standards were prepared by diluting the 10 mg L−1 stock stan-
dards of single-element and multi-element standards with 2%
(v/v) HNO3 and 0.5% (v/v) HCl. For most elements, the stan-
dard concentrations ranged from 0 to 50 ng per gram of solution
(ppb). Concentrations for the platinum group elements, gold,
and mercury ranged from 0 to 1 ppb to reduce the potential for
memory effects and element carry over. The isotopes used for
analysis and the calibration concentration ranges of the stan-
dards are reported in Table 2. Quality control and calibration
verification samples containing all elements under study, in-
cluding the continuing calibration blank (CCB), low-level con-
tinuing calibration verification (LLCCV) standard, and contin-
uing calibration verification (CCV) standardwere also prepared
separately from stock solutions. The calibration blank and CCB
were prepared separately from the sample matrix (usually 2%
HNO3 and 0.5% HCl) but served different analytical purposes.
The calibration blank was used as a calibration standard with
zero analyte concentration, whereas the CCB was used to pe-
riodically verify the absence of carryover from one sample to
the next. The LLCCV concentration was approximately equal
to the second lowest non-blank standard, and the CCV con-
centration was approximately the midpoint of the calibration
standard range. These control and calibration samples were
measured throughout each analysis run, typically every five
samples, as described below, to continually verify the accuracy
of the measurements.
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Sample Preparation
Samples were prepared for analysis by closed-vessel
microwave-assisted digestion as described above. All relevant
solution parameters (sample mass, tube mass, diluent added)
weremeasured gravimetrically at a precision of±0.1mg. A typ-
ical digestion solution comprised 2 mL of concentrated HNO3
and 2 mL of concentrated HCl. For some organic materials,
30% hydrogen peroxide (1 mL) was added to enhance oxida-
tive degradation processes. In some cases, 0.7mLHF (50%) was
added to digest materials that could not be digested completely
with HNO3 and HCl (e.g., talc, TiO2, SiO2). Decisions about the
addition of HF and hydrogen peroxide were made on the basis
of material knowledge and visual examination of the diluted
samples. When solid was observed in the diluted sample, ad-
justments were made to the digestion cocktail (e.g., addition
of H2O2 and HF) to minimize the solid, and samples digested
with and without the additives were run to establish recoveries
under both conditions. Typically, 0.2–0.3 g of an excipient was
digested in about 3 mL of an acid cocktail at 190°C in Teflon
vessels. The vessels were brought to temperature over a period
of 10 min, and temperature was maintained for 20 more min-
utes before allowing the vessels to cool to room temperature
over the course of approximately 30 min. The cooled samples
were then delivered to 50 mL trace metal free polypropylene
tubes (VWR) and diluted with 18.2 M-cm DI water to a vol-
ume of about 30 mL (diluent measured gravimetrically) for a
total dilution factor of about 100 with respect to the original
sample mass. This resulted in a solution composition of about
2% (v/v) HNO3 and 0.5% (v/v) HCl, accounting for estimated
loss due to NOx formation and HCl evaporation.
Sample Analysis
Digested and diluted samples were prepared and analyzed in
23 separate ICP-MS runs over a span of about 9 months. Af-
ter tuning the instrument and determining system suitabil-
ity, the samples were analyzed for all elementals shown in
Table 2. A typical measurement sequence was programmed as
follows. Calibration standards were run at the beginning of the
sequence including a matrix blank, a calibration blank, cali-
bration standards, CCB, LLCCV, CCV, and another calibration
blank. The calibration standards were used to establish a linear
calibration curve for each element. After the initial measure-
ment of calibration and quality control standards, the remain-
der of the sequence included the following: (1) measurement
of five samples, (2) measurement of CCB, LLCCV, calibration
blank, CCV, and another calibration blank. Parts (1) and (2)
were repeated sequentially until all samples in the measure-
ment run were completed. LLCCV and CCV served as qual-
ity control standards to assess the recoveries of each element
in each run. If the recovered concentrations did not agree to
within ±20% of the theoretical concentrations for all continu-
ing calibration validation solutions during the analysis, further
investigation of the results was conducted and, when necessary,
repeated. Results from approximately 10 samples were based
on repeated measurements performed in the last three mea-
surement groups. Details regarding measurement groups can
be found in the Supporting Material. Quality control standards
also provided a measure of the variance associated with the
analysis of samples.
In each run, 24 elements including Cd, Pb, As, Hg, Co, V,
Ni, Tl, Au, Pd, Ir, Os, Rh, Ru, Se, Ag, Pt, Li, Sb, Ba, Mo, Cu,
Sn, and Cr were measured, some at multiple isotopic masses to
identify and correct for interferences. A collision cell contain-
ing helium was used during analysis of some elements with
common polyatomic interferences to reduce the interfering ion
concentrations. V, Cr, Co, Ni, Cu, and Mo were determined in
He mode with a He flow rate of 4.5 mL min−1, and As-75 and
Se-78 were monitored in high He mode with a helium flow rate
of 6.0 mL min−1. The rest of the elements were analyzed with
no gas in the collision cell.
Linear calibration curves were established using linear re-
gression on the signal levels against the gravimetrically deter-
mined element concentrations for each element at each isotopic
mass under study. The coefficient of determination (R2) values
for the signal response functions were generally greater than
0.999. Pb counts were corrected for geographical differences in
isotopic distribution by calibration on the sum of Pb-206, Pb-
207, and Pb-208 counts, except when samples contained large
concentrations of bismuth. In this case, the bismuth signal may
overlap with Pb-208, and the Pb-206 and Pb-207 signals were
used to estimate Pb concentration. The isotopes Cd-106 and
Cd-108 were also monitored for the correction of Cd-111 inter-
ferents.
RESULTS
Table 2 displays the isotopes used for analysis, calibration
sample concentration ranges and solution limits of detection
(LODs) for each element which is listed in the ICH Q3D guide-
line. The Q3D element classes, which are intended to assist
the risk assessment of elemental impurities in drug products,
are also identified, and elements that are listed in Q3D but
are not covered by USP <232> are indicated with an aster-
isk. In each run, the instrumental LODs for each element were
established as three times the SD of all blanks (CCBs and cal-
ibration blanks) measured in that run, and the LODs listed
in Table 2 are averages of 23 ICP-MS runs performed over a
period of approximately 9 months. The reported LODs are all
less than 1 ppb, and the highest LOD is 0.8 ppb for Cu, which
is known to have several interferences. Selenium has a LOD
of 0.7 ppb owing to argon and chloride molecular ion inter-
ferences. Twenty (20) of the remaining 22 element LODs are
below 0.2 ppb, and the ICH Q3D Class 1 elements (Cd, Pb, As,
and Hg) have LODs below 0.06 ppb. Although chloride ion in
the matrix is known to interfere with As and Se, the collision
cell in high He mode substantially reduced these polyatomic
interferences. When dilution factors of 100 are used to di-
lute the original excipient samples, the resulting LODs in the
pharmaceutical materials are expected to be in the range of
1–20 ppb for most elements. Assuming that limits of quanti-
tation (LOQs) are 3.3 times the LODs, LOQs are expected to
be in the range of 3–65 ppb for most elements. The Q3D Op-
tion 1 concentrations can be used to put these LOQs in context.
The Option 1 concentrations are calculated by dividing the el-
ement specific PDEs by 10 g, and indicate concentrations that
may be present in drug products with maximum daily doses
of up to 10 g without exceeding the PDEs. The Q3D Option
1 concentrations range from 100 ppb to 1100 ppm. Thus the
sensitivities characterized by the LOQs discussed above are
adequate for quantitative analysis at all final ICH Q3D Option
1 concentrations by oral, parenteral and inhalation routes of
administration.
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Table 3. Summary of Quality Control Standards Performances
Element Isotope LLCCV Recovery CCV Recovery
Cd 111 98% ± 4% 99% ± 3%
Pb 208 98% ± 8% 99% ± 8%
As 75 94% ± 12% 98% ± 10%
Hg 202 91% ± 16% 99% ± 8%
Co 59 98% ± 5% 100% ± 6%
V 51 101% ± 8% 101% ± 6%
Ni 60 97% ± 8% 100% ± 6%
Tl 205 97% ± 11% 99% ± 13%
Au 197 95% ± 10% 100% ± 6%
Pd 105 92% ± 24% 92% ± 22%
Ir 193 95% ± 8% 99% ± 4%
Os 189 89% ± 22% 98% ± 6%
Rh 103 93% ± 10% 100% ± 3%
Ru 101 93% ± 12% 95% ± 22%
Se 78 95% ± 9% 99% ± 10%
Ag 107 98% ± 4% 99% ± 3%
Pt 195 95% ± 8% 98% ± 6%
Li 7 97% ± 4% 99% ± 3%
Sb 121 97% ± 6% 100% ± 4%
Ba 137 100% ± 5% 101% ± 3%
Mo 95 98% ± 5% 100% ± 6%
Cu 63 92% ± 15% 96% ± 11%
Sn 118 96% ± 6% 99% ± 5%
Cr 52 99% ± 8% 100% ± 6%
The recoveries for the LLCCV and CCV quality control sam-
ples are displayed in Table 3. The analyses of these two stan-
dards were repeated every five samples within each run tomon-
itor the stability of the system and assure continued quality of
the measurements. The calculated concentration of each ele-
ment in the LLCCV and CCV samples was compared with the
theoretical concentration of the element in the gravimetrically
prepared samples. Recovery values displayed in Table 3 are the
means and SDs of CCV and LLCCV samples measured in 23
runs over a period of approximately 9 months. The mean re-
coveries were between 89% and 101%, with most being close to
100%. The LLCCVs display higher variability than the CCVs
owing to the lower concentrations of these samples. Variability
is typically highest in the elements with calibration standard
ranges of 0.01–1 ppb (e.g., Hg and the Pt series) and elements
with known interferences (e.g., Se, Cu, and As). Variability in
Os and Pd may also result from facile formation of volatile
oxides for these elements. The CCV recoveries display lower
variability and confidence intervals between 83% and 105%.
These results demonstrate satisfactory quality control of the
measurement system.
The summary results of the analysis of 190 excipient sam-
ples and 15 drug substance samples are shown in Tables 4–7.
The drug substances are displayed in the bottom 8 rows of
the tables. The complete data set used to generate Tables 4–7
is available in the Supporting Material. The sample solution
concentrations were predicted from signal levels using the lin-
ear regression calibration equations, and concentrations in the
original materials were determined after multiplying the so-
lution concentrations by the sample dilution factors to give
concentrations in micrograms of the elemental impurity per
gram of excipient (parts per million, ppm) to 2 decimal places.
Samples with predicted concentrations lower than the LOD for
a given element were labeled as <LOD. Elemental impurities
with concentrations less than 0.005 ppm in the samples were
rounded to a value of 0.00. SDs of 0.00 in Tables 4–7 indicate
values less than 0.005. Elemental impurity concentrations in
the excipients and drug substances without rounding are given
in the Supporting Material.
When several samples of a specific excipient were available,
the average elemental impurity concentrations and SDs were
reported in Tables 4–7. Some of these samples were multi-
ple lots from the same manufacturer, and some were sampled
across manufacturers. This level of detail has not been pro-
vided in Tables 4–7, but the interested reader may assess the
within-supplier and between-supplier variabilities in these con-
centrations by examining the data provided in the Supporting
Material.
Table 4 displays the summary concentrations of Q3D Class
1 impurities in the pharmaceutical excipients and drug sub-
stances evaluated in this work. With the exception of some
results for Pb, the measured ICH Q3D Class 1 elemental impu-
rity concentrations shown in Table 4 were found to be extremely
low in these materials. Levels of Cd and Hg were found to be
less than 1 ppm in all excipients analyzed, and 10 ppb or less
in drug substances. Titanium dioxide showed relatively high
and variable Pb concentrations of 2.15 ± 1.81 ppm. Synthetic
excipients and drug substances and cellulose-based materials
had Class 1 levels either below the LODs or in the 1–10 ppb
range. Some excipients with metal counter ions had Class 1
concentrations in the 100 ppb range, and excipients and drug
substances expected to be sourced from mined raw materials
also had Class 1 concentrations in the 100–900 ppb range. Four
of the excipients exceed the ICH Q3D Option 1 oral concentra-
tions for 1 or more elemental impurities: TiO2 and Zn Stearate
exceed the Q3D Option 1 concentration for Pb and MgOH and
CaCO3 exceed the Q3D Option 1 concentration for Cd.
Table 5 displays the summary concentrations for the Q3D
Class 2B elements. All materials displayed very low concen-
trations of the ICH Q3D Class 2B elements including Ag, Au,
Tl, and platinum group elements, and no excipients or drug
substances exceeded the ICH Q3D Option 1 oral concentra-
tions for Class 2B elements. Q3D Class 2B comprises precious
metals and other elements that are unlikely to be present in
drug products unless they are intentionally added. Most of the
excipients were below the element LODs. Silicone elastomer
and silicone tacky gel samples were exceptions, and were found
to contain Pt concentrations of 3.75 ± 3.76 ppm and 6.39 ±
0.14 ppm, respectively. These samples use Pt-containing cata-
lysts during polymer synthesis. Of the materials that had mea-
sureable levels of Class 2B elements, one (bismuth subsalicy-
late) had Ag at a level of 0.7 ppm and one (Zn Stearate) had Se
at a level of 0.14 ppm. All others were less than 0.09 ppm. The
results for the Class 2B elements are consistent with the expec-
tation that these elements are rarely found in pharmaceutical
materials unless they are intentionally added.
Table 6 shows the summary concentrations of the Q3D
Class 2A elements, and demonstrates that the ICH Q3D Class
2A elements (Co, V, andNi) were also found at low levels inmost
excipients and drug substances. Iron oxides showed relatively
high concentrations (100 ppm) of V, Ni, and Co, and the mean
values of these concentrations exceeded the ICH Q3D Option 1
oral concentrations. Carbonyl iron samples also exhibited lev-
els of Ni that exceeded the Option 1 oral concentrations. From
these results, it appears that Class 2A elements may be com-
monly found in Fe containing excipients and drug substances.
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Table 4. Class 1 Elemental Impurity Concentrations in Excipient Samples. Concentrations given as <LOD Indicate Levels Below the Method
Limit of Detection
N (Number
of Samples) Materials Name Cd (ppm) Pb (ppm) As (ppm) Hg (ppm)
5 Ferric oxide red <LOD 0.37 ± 0.21 0.66 ± 0.32 0.00 ± 0.00
5 Ferric oxide yellow <LOD 0.28 ± 0.36 0.80 ± 0.41 0.00 ± 0.01
5 Ferrous oxide black <LOD 0.03 ± 0.03 0.04 ± 0.01 <LOD
11 Talc 0.00 ± 0.00 0.19 ± 0.06 0.17 ± 0.05 0.01 ± 0.01
7 Titanium dioxide 0.04 ± 0.02 2.15 ± 1.81 0.08 ± 0.13 0.01 ± 0.02
3 Silicon dioxide 0.02 ± 0.01 0.12 ± 0.04 0.01 ± 0.00 0.01 ± 0.00
13 Calcium phosphates 0.03 ± 0.01 0.03 ± 0.01 0.24 ± 0.18 0.00 ± 0.00
5 Carrageenan 0.25 ± 0.22 0.15 ± 0.10 0.52 ± 0.18 0.01 ± 0.01
26 Calcium carbonate 0.77 ± 0.10 0.18 ± 0.59 0.04 ± 0.04 0.00 ± 0.01
17 Sodium alginate 0.01 ± 0.01 0.42 ± 0.30 0.42 ± 0.20 0.00 ± 0.00
9 Silicone elastomer 0.00 ± 0.00 0.01 ± 0.01 0.00 ± 0.01 <LOD
9 Simethicone 0.00 ± 0.00 <LOD <LOD <LOD
9 Simethicone emulsion 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 <LOD
6 Dimethicone <LOD 0.00 ± 0.00 <LOD <LOD
3 Silicone tacky gel 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.01 <LOD
3 Polydimethysiloxane 0.00 ± 0.00 0.01 ± 0.02 0.00 ± 0.00 <LOD
17 Povidone 0.00 ± 0.00 0.00 ± 0.01 0.00 ± 0.01 <LOD
3 Ethylcellulose <LOD <LOD 0.00 ± 0.00 <LOD
11 Carboxymethylcellulose 0.00 ± 0.00 0.09 ± 0.27 0.00 ± 0.01 <LOD
8 Hydroxypropylcellulose 0.00 ± 0.00 0.00 ± 0.00 <LOD <LOD
6 Hypromellose 0.00 ± 0.00 0.01 ± 0.00 <LOD <LOD
1 Zinc stearate 0.31 1.05 <LOD <LOD
1 Magnesium stearate NF/EP 0.00 0.01 0.02 <LOD
1 Magnesium hydroxide granular 0.84 0.33 0.55 <LOD
1 Magnesium carbonate 0.43 0.07 0.13 <LOD
1 Blue #1 0.00 0.03 0.01 0.03
1 Red #27 Al.Lake 0.00 0.21 0.16 <LOD
1 Imidurea <LOD <LOD <LOD 0.02
1 N-Methyl-2-pyrrolidone <LOD <LOD <LOD <LOD
1 2,5-Dioxo-4-imidazolidinyl <LOD <LOD 0.00 0.04
3 Tetracaine HCl <LOD 0.01 ± 0.01 <LOD <LOD
3 Orphenadrine citrate <LOD <LOD <LOD <LOD
2 Procainamide HCl 0.01 ± 0.01 <LOD <LOD <LOD
3 Benzonatate 0.00 ± 0.00 0.00 ± 0.01 <LOD <LOD
1 Flunixin meglumine 0.00 0.00 <LOD <LOD
1 Bismuth subsalicylate 0.00 0.15 0.02 <LOD
1 Carbonyl iron 0.01 <LOD 0.04 0.01
1 Bemotrizinol <LOD <LOD <LOD <LOD
Concentrations given as 0.00 indicate levels below the stated precision but above the LOD. Uncertainties given as 0.00 are below the stated precision. The bottom
8 rows display results for some drug substances.
The Q3D Class 3 elements have relatively low toxicity by
the oral route of administration, with oral PDE ranging from
550–11,000 :g/day. PDEs for parenteral and inhalation routes
are lower than the oral PDEs. Table 7 displays summary con-
centrations of the Q3D Class 3 elements. Data in Table 7 iden-
tify several excipients with relatively high levels of ICH Q3D
Class 3 elements when compared with the levels of Class 1
and 2 elemental impurities in these same materials. For ex-
ample, Fe oxides show elevated levels of Cr, Mo, Sn, and/or
Cu, CaCO3 show elevated levels of Cr and Ba, and talc, car-
rageenans, alginates, and Zn stearate show elevated levels of
Ba compared with concentrations of their Class 1 and 2 el-
ements. However, none of these levels exceed the ICH Q3D
Option 1 concentration limits for oral or parenteral products.
Thus, the observed levels of elemental impurities in these ex-
cipients are low relative to the relevant safety thresholds in
finished drug products. Drug substances examined in this sur-
vey have extremely low levels of the ICHClass 3 elements, with
the exception of carbonyl iron, which exhibits low levels of Mo
and Cr.
DISCUSSION
Perhaps the most remarkable feature of this data set taken
as a whole is that elemental impurity concentrations in the
excipients examined within this study are generally low, and
for most excipients, often well below 1 microgram of impurity
per gram of excipient. However, some excipients had higher
concentrations of certain elemental impurities when compared
with the average values observed across all excipients. For in-
stance, relatively high concentrations of Pb in TiO2 and Class
2A and Class 3 elemental impurities in iron oxides were dis-
cussed above, but these observations were not unexpected. It is
also not surprising that calcium carbonate and other mined ex-
cipients showed elevated concentrations of selected elemental
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Table 6. Class 2A Elemental Impurity Concentrations in Excipient Samples Concentrations given as <LOD Indicate Levels Below the Method
Limit of Detection
N (Number of Samples) Materials Name Co (ppm) V (ppm) Ni (ppm)
5 Ferric oxide red 38.6 ± 16.6 436 ± 48 96.0 ± 13.1
5 Ferric oxide yellow 37.8 ± 13.5 407 ± 20 57.7 ± 30.6
5 Ferrous oxide black 123.5 ± 50.9 43.9 ± 0.1 154.4 ± 31.9
11 Talc 3.31 ± 2.31 5.30 ± 2.81 12.9 ± 9.1
7 Titanium dioxide 0.01 ± 0.02 3.69 ± 1.89 0.19 ± 0.15
3 Silicon dioxide 0.02 ± 0.01 0.14 ± 0.02 1.95 ± 1.11
13 Calcium phosphates 0.06 ± 0.05 3.92 ± 3.22 1.50 ± 1.23
5 Carrageenan 0.10 ± 0.08 0.47 ± 0.12 0.23 ± 0.12
26 Calcium carbonate 0.16 ± 0.03 1.78 ± 0.32 2.85 ± 0.68
17 Sodium alginate 0.02 ± 0.03 0.17 ± 0.25 0.37 ± 0.20
9 Silicone elastomer 0.00 ± 0.00 0.00 ± 0.01 0.12 ± 0.06
9 Simethicone 0.01 ± 0.00 <LOD 0.28 ± 0.02
9 Simethicone emulsion 0.04 ± 0.01 0.01 ± 0.00 2.92 ± 0.66
6 Dimethicone 0.00 ± 0.00 <LOD 0.02 ± 0.04
3 Silicone tacky gel 0.00 ± 0.00 <LOD 0.00 ± 0.01
3 Polydimethysiloxane 0.00 ± 0.00 <LOD 0.01 ± 0.02
17 Povidone 0.01 ± 0.03 0.01 ± 0.01 0.02 ± 0.03
3 Ethylcellulose 0.00 ± 0.00 0.01 ± 0.01 7.11 ± 2.60
11 Carboxymethylcellulose 0.02 ± 0.02 0.00 ± 0.00 0.54 ± 0.53
8 Hydroxypropylcellulose 0.02 ± 0.03 0.00 ± 0.01 0.07 ± 0.04
6 Hypromellose 0.00 ± 0.00 0.00 ± 0.01 0.44 ± 0.21
1 Zinc stearate <LOD <LOD 0.66
1 Magnesium stearate NF/EP 0.00 <LOD 0.16
1 Magnesium hydroxide granular 0.06 1.43 2.49
1 Magnesium carbonate 0.01 0.32 0.73
1 Blue #1 0.01 0.26 1.58
1 Red #27 Al.Lake 0.02 1.21 0.84
1 Imidurea <LOD 0.02 <LOD
1 N-Methyl-2-pyrrolidone <LOD <LOD <LOD
1 2,5-Dioxo-4-imidazolidinyl <LOD 0.03 <LOD
3 Tetracaine HCl 0.00 ± 0.00 <LOD 0.02 ± 0.00
3 Orphenadrine citrate 0.00 ± 0.00 <LOD 0.01 ± 0.02
2 Procainamide HCl <LOD <LOD 0.01 ± 0.01
3 Benzonatate <LOD <LOD 0.03 ± 0.05
1 Flunixin meglumine <LOD <LOD 0.18
1 Bismuth subsalicylate <LOD <LOD 0.00
1 Carbonyl iron 0.01 <LOD 36.7
1 Bemotrizinol <LOD <LOD 0.01
Concentrations given as 0.00 indicate levels below the stated precision but above the LOD. Uncertainties given as 0.00 are below the stated precision. The bottom
8 rows display results for some drug substances.
impurities relative to concentrations of these same elemental
impurities in other excipients. Most importantly, in the ma-
jority of cases when the observed concentrations of elemental
impurities from these excipients were compared with relevant
limits for potentially harmful elemental concentrations, the ex-
cipient’s elemental impurity levels were found to be well below
concentrations of concern.
A second key finding of this work was that, unless intention-
ally added, Class 2B metals were not observed at significant
concentrations in any materials tested. This finding further
supports the ICH Q3D approach to Class 2B elemental impu-
rities during assessment of the risk for inclusion of elemental
impurities in drug products. The results of this survey substan-
tiate that it is generally appropriate to only include the Class
2B elemental impurities in a risk assessment when they are
intentionally added to a component of the drug product.
Of particular interest to pharmaceutical manufacturers are
scenarios where the observed concentrations of elements in any
excipients would result in drug products that would exceed
the PDEs for elemental impurities. Although unlikely, based
on the results of this survey, PDE limits for a given elemental
impurity could be exceeded if the drug product delivered a large
mass of one or more excipients with elevated concentrations
of elemental impurities to the patient. Based on comparison
of the observed element concentrations in these excipients to
the ICH Q3D Option 1 concentrations, for most excipients, the
mass of excipient delivered to the patient would typically need
to exceed 10 g in order for the elemental impurity level in the
drug product to exceed the Q3D Option 1 limit.
As additional data become available, trends in elemental im-
purities levels in excipients may emerge, but it is important to
stress that this survey only provides a snapshot of elemental
impurity levels in a limited number of pharmaceutical materi-
als from certain suppliers. No conclusions can be drawn from
these data that preclude the need for pharmaceutical manu-
facturers to perform a risk assessment with the suppliers and
grades of excipients used in their drug products. Additionally,
the limited number of samples tested in this study may not
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Table 7. Class 3 Elemental Impurity Concentrations in Excipient Samples Concentrations given as <LOD Indicate Levels Below the Method
Limit of Detection
N (Number
of Samples) Materials Name Li (ppm) Sb (ppm) Ba (ppm) Mo (ppm) Cu (ppm) Sn (ppm) Cr (ppm)
5 Ferric oxide red 0.15 ± 0.10 0.13 ± 0.10 1.04 ± 1.66 2.47 ± 0.88 13.0 ± 8.9 4.41 ± 4.51 32.5 ± 10.8
5 Ferric oxide yellow <LOD 0.17 ± 0.16 0.41 ± 0.07 2.87 ± 1.87 12.4 ± 7.1 2.47 ± 1.04 26.2 ± 12.0
5 Ferrous oxide black 0.05 ± 0.00 0.17 ± 0.00 2.00 ± 3.06 0.82 ± 0.00 5.60 ± 0.02 0.78 ± 0.00 7.94 ± 0.09
11 Talc 2.47 ± 1.58 0.01 ± 0.02 6.88 ± 11.96 0.35 ± 0.72 0.10 ± 0.21 0.24 ± 0.16 9.86 ± 9.51
7 Titanium dioxide 0.05 ± 0.01 0.01 ± 0.02 14.8 ± 32.7 0.40 ± 0.25 0.17 ± 0.27 0.25 ± 0.14 0.92 ± 0.25
3 Silicon dioxide <LOD 0.03 ± 0.01 0.86 ± 0.80 0.13 ± 0.09 0.05 ± 0.05 <LOD 1.82 ± 0.97
13 Calcium phosphates 0.39 ± 0.41 0.10 ± 0.05 2.11 ± 1.76 2.60 ± 1.06 0.15 ± 0.15 0.01 ± 0.01 5.11 ± 5.99
5 Carrageenan 0.11 ± 0.03 0.01 ± 0.00 1.73 ± 0.57 0.05 ± 0.02 0.33 ± 0.13 0.01 ± 0.01 0.31 ± 0.14
26 Calcium carbonate 0.16 ± 0.04 0.01 ± 0.01 19.9 ± 22.7 0.01 ± 0.05 0.36 ± 0.13 0.00 ± 0.00 3.64 ± 0.50
17 Sodium alginate 0.10 ± 0.14 0.02 ± 0.02 59.4 ± 70.3 0.21 ± 0.15 0.36 ± 0.90 0.03 ± 0.05 0.83 ± 0.45
9 Silicone elastomer <LOD 0.00 ± 0.00 0.13 ± 0.13 <LOD <LOD <LOD 0.11 ± 0.06
9 Simethicone <LOD <LOD 0.04 ± 0.03 0.02 ± 0.00 0.01 ± 0.01 0.09 ± 0.00 0.19 ± 0.02
9 Simethicone emulsion <LOD <LOD 0.04 ± 0.01 0.26 ± 0.05 0.05 ± 0.01 0.09 ± 0.04 2.21 ± 0.42
6 Dimethicone <LOD <LOD <LOD <LOD <LOD 0.03 ± 0.08 0.03 ± 0.04
3 Silicone tacky gel <LOD <LOD <LOD <LOD <LOD 0.02 ± 0.02 0.01 ± 0.01
3 Polydimethysiloxane <LOD 0.01 ± 0.02 0.00 ± 0.00 <LOD <LOD 0.09 ± 0.16 <LOD
17 Povidone <LOD 0.00 ± 0.00 0.03 ± 0.06 0.01 ± 0.02 0.00 ± 0.01 0.01 ± 0.03 0.01 ± 0.01
3 Ethylcellulose 0.01 ± 0.01 <LOD 0.53 ± 0.28 <LOD 0.24 ± 0.06 <LOD 0.08 ± 0.04
11 Carboxymethylcellulose 0.06 ± 0.15 0.00 ± 0.00 1.16 ± 0.91 0.04 ± 0.05 0.03 ± 0.04 0.05 ± 0.08 0.20 ± 0.09
8 Hydroxypropylcellulose 0.00 ± 0.01 <LOD 0.14 ± 0.18 0.01 ± 0.02 0.05 ± 0.07 0.08 ± 0.05 0.07 ± 0.09
6 Hypromellose 0.01 ± 0.01 <LOD 0.19 ± 0.03 0.07 ± 0.06 0.02 ± 0.02 0.15 ± 0.24 0.60 ± 0.29
1 Zinc stearate <LOD <LOD 37.49 <LOD <LOD <LOD 0.02
1 Magnesium stearate
NF/EP
0.03 <LOD 0.11 <LOD <LOD <LOD 0.02
1 Magnesium hydroxide
granular
0.00 0.11 0.08 2.60 1.08 0.05 0.02
1 Magnesium carbonate <LOD 0.01 0.22 0.06 <LOD <LOD 0.94
1 Blue #1 0.07 0.00 0.10 1.10 0.49 <LOD 0.61
1 Red #27 Al.Lake 0.03 0.01 11.65 0.41 5.45 0.28 2.38
1 Imidurea <LOD <LOD 0.01 <LOD <LOD <LOD 0.03
1 N-Methyl-2-pyrrolidone <LOD <LOD <LOD <LOD <LOD <LOD <LOD
1 2,5-Dioxo-4-imidazolidinyl <LOD <LOD 0.00 <LOD 0.06 0.03 <LOD
3 Tetracaine HCl <LOD <LOD 0.14 ± 0.24 <LOD <LOD <LOD 0.03 ± 0.01
3 Orphenadrine citrate <LOD <LOD 0.15 ± 0.26 <LOD <LOD <LOD 0.03 ± 0.03
2 Procainamide HCl <LOD <LOD <LOD <LOD <LOD <LOD 0.02 ± 0.00
3 Benzonatate <LOD <LOD 0.00 ± 0.00 <LOD <LOD <LOD 0.01 ± 0.02
1 Flunixin meglumine <LOD <LOD <LOD 0.14 <LOD <LOD 0.52
1 Bismuth subsalicylate 0.04 0.00 <LOD <LOD <LOD <LOD 0.10
1 Carbonyl iron 0.04 <LOD 0.04 37.58 <LOD <LOD 9.13
1 Bemotrizinol 0.01 <LOD <LOD <LOD <LOD <LOD 0.00
Concentrations given as 0.00 indicate levels below the stated precision but above the LOD. Uncertainties given as 0.00 are below the stated precision. The bottom
8 rows display results for some drug substances.
reflect the natural variability of elemental impurity levels for
somematerials. In particular, somemined excipients are known
to exhibit relatively large excursions over time from mean lev-
els of certain elemental impurities.
This survey presents determinations of 24 elements in 205
pharmaceuticalmaterials for a total ofmore than 4900 determi-
nations. Quality control samples and system suitability proce-
dures were used throughout the survey to assure the accuracy
of the results. Although a full uncertainty budget is out of scope
for this survey, certain considerations for minimizing measure-
ment error from instrumental sources and sample preparation
sources are discussed below.
Inductively coupled plasma mass spectrometry provides ex-
tremely low detection limits, ranging from part per trillion
(ppt) to part per billion (ppb) for many elements. It is a sen-
sitive and selective technique that is quantitative and has
acceptable precision at concentrations that are suitable to
demonstrate compliance with safety-based PDEs for many
pharmaceutical products. The most challenging shortcoming of
ICP-MS is the existence of non-spectroscopic and spectroscopic
interferences for some elements. These interferences are gen-
erally known, and strategies have been or can be developed to
overcome these challenges. To reduce the matrix interferences,
calibration standards or matrix blanks should be prepared in
the samematrix as the samples. When feasible, dilution factors
in the range of 50–100 may assist to minimize the influence of
the sample to matrix effects. Argon background interference
and oxygen-, nitrogen-, and hydrogen-containing interferences
are significant because of their constant introduction to the sys-
tem. In some cases, these interferences can be avoided by ju-
dicious selection of analytical isotope. Polyatomic interferences
which result from samples containing sodium, halogen, carbon,
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and oxygen can be decreased by collision or reaction cells. Col-
lision cells are based on the observation that polyatomic ions
undergo more collisions than atomic ions when exposed to low
pressure helium, which deflects the interferent out of the de-
tection path. This survey also demonstrates that elements with
known interferences exhibit higher LODs and greater variabil-
ity in quality control samples than elements that are less likely
to have interferences.
Recovery of elemental impurities from the sample matrix
is a challenging consideration for analysis of pharmaceutical
materials. Microwave-assisted digestion provides an approach
to sample preparation which can be used to assess the maxi-
mum mass of an elemental impurity that may be delivered to
a patient in a specified drug product. In this study, digestion of
excipients such as silicon dioxide, titanium oxide, and talc uti-
lized HF to maximize dissolution of the solid matrix. Additional
safety precautions must be exercised whenHF is used. Concern
over the safe handling of HF prompted a review of the recovery
of elemental impurities with and without HF in a spiked sam-
ple of talc that is not expected to be totally solubilized by HNO3
digestion.Mg and Si spike recoveries were 800% and 5000%, re-
spectively, indicating that the observed levels of these elements
were elevated because of decomposition of the magnesium sil-
icate structure of the material in the presence of HF. On the
other hand, most elements that were expected to be present as
extraneous impurities exhibited recoveries in the 90%–110%
range under both conditions, indicating that unbound elemen-
tal impurities can be adequately analyzed without the use of
HF in talc. Although further investigation is required, these
results indicate that HF may be of limited use when analyzing
elemental impurities in hard-to-digest materials.
A number of element-specific precautions are also warranted
when analyzing complex products for numerous elements, such
as is required in the analysis of USP <232> or ICH Q3D ele-
mental impurities. When boron is of interest, it is known that
carry over can occur from boron’s tendency to volatilize as boric
acid from the sample solution inside the spray chamber.9 It
is also well known that Hg may volatilize and be absorbed in
the ICP sample introduction system, which can require a long
wash out time and increase Hg background levels. For this rea-
son, the concentrations of Hg standards were minimized in this
study. In addition, Hg is typically stabilized in solution through
the addition of HCl in the digestion matrix. Au has also been
used as a Hg stabilizer, though there is some controversy over
the relative merits of Au and Cl for Hg stabilization.10 Finally,
some researchers have reported that facile oxidation of Os to
the volatile and toxic OsO4 oxide can result in challenges dur-
ing the quantitative determination of Os.11 The volatile nature
of this oxide can also result in carry over. It has been proposed
that aqua regia provides a bettermatrix for Os recovery in some
cases.11
CONCLUSIONS
This survey covers 24 elements in 205 samples for a total of
over 4900 determinations. The results shown in Table 3 sug-
gest that these determinations are accurate. Overall, low levels
of elemental impurities were found in the synthetic excipients
examined in this survey, as well as excipients such as cellu-
loses that are highly processed before use. Some mined excip-
ients exhibit relatively elevated levels of elemental impurities
compared with other materials examined in this survey, but
in many cases these levels were still low in comparison with
relevant PDEs. Although this survey provides some evidence
that elemental impurity levels in excipients are not likely to
result in excessive levels in drug products, these results can-
not be considered definitive. Lot-to-lot and supplier-to-supplier
variability have not been addressed thoroughly in this survey.
As noted above, no conclusions can be drawn from these data
that preclude the need for pharmaceutical manufacturers to
perform a risk assessment with the suppliers and grades of
excipients used in their drug products.
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